Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients

References

• Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Park Relat Disord. 2015;21(10):1133–1144. doi:10.1016/j.parkreldis.2015.07.020
   PubMed Web of Science ®Google Scholar
• Titova N, Martinez-Martin P, Katunina E, Chaudhuri KR. Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed. J Neural Transm. 2017;124(12):1529–1537. doi:10.1007/s00702-017-1799-329116411
   PubMed Web of Science ®Google Scholar
• Krüger R, Hilker R, Winkler C, et al. Advanced stages of PD: interventional therapies and related patient-centered care. J Neural Transm. 2016;123(1):31–43. doi:10.1007/s00702-015-1418-026138439
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–149. doi:10.1016/S1474-4422(13)70293-X24361112
   PubMed Web of Science ®Google Scholar
• Antonini A, Poewe W, Chaudhuri KR, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Park Relat Disord. 2017;45:13–20. doi:10.1016/j.parkreldis.2017.09.018
   PubMed Web of Science ®Google Scholar
• Juhász A, Aschermann Z, Ács P, et al. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: an open-label study. Parkinsonism Relat Disord. 2017;37:79–86. doi:10.1016/j.parkreldis.2017.02.00128185758
   PubMed Web of Science ®Google Scholar
• Udd M, Lyytinen J, Eerola-Rautio J, et al. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease. Brain Behav. 2017;7(7):1–7. doi:10.1002/brb3.737
   Web of Science ®Google Scholar
• Sensi M, Cossu G, Mancini F, et al. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: italian multicentre survey of 905 patients with long-term follow-up. Park Relat Disord. 2017;38(February):90–92. doi:10.1016/j.parkreldis.2017.02.020
   Web of Science ®Google Scholar
• Wang L, Li J, Chen J. Levodopa-carbidopa intestinal gel in Parkinson’s disease: a systematic review and meta-analysis. Front Neurol. 2018;9(July). doi:10.3389/fneur.2018.00620
   Web of Science ®Google Scholar
• Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease. Eur J Neurol. 2012;19(8):1079–1085. doi:10.1111/j.1468-1331.2012.03679.x22360705
   PubMed Web of Science ®Google Scholar
• Băjenaru O, Ene A, Popescu BO, et al. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience. J Neural Transm. 2016;123(4):407–414. doi:10.1007/s00702-015-1496-z26699635
   PubMed Web of Science ®Google Scholar
• Szász JA, Constantin VA, Orbán-Kis K, et al. Profile of patients with advanced Parkinson’s disease suitable for device-aided therapies: retrospective data of a large cohort of romanian patients. Neuropsychiatr Dis Treat. 2019;15:3187–3195. doi:10.2147/ndt.s23005232009788
   PubMed Web of Science ®Google Scholar
• Szász JA, Szatmári S, Constantin V, et al. Characteristics of levodopa treatment in advanced Parkinson’s disease in the experiences of the neurology clinics of Târgu Mures, Romania [Az orális levodopakezelés jellegzetességei előrehaladott Parkinson-kórban a marosvásárhelyi neurológiai klinikák tap]. Orv Hetil. 2019;160(17):662–669. doi:10.1556/650.2019.3135431010306
   PubMed Web of Science ®Google Scholar
• Szász J, Constantin V, Orbán‐Kis K, et al. Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa‐carbidopa intestinal gel infusion: data from 107 tested patients. Mov Disord. 2018;33:171.
   Web of Science ®Google Scholar
• Szasz J, Constantin V, Orban-Kis K, et al. Spectrum of motor complications in advanced Parkinson’s disease: data from a large Romanian case series evaluated for suitability for device aided therapy. Mov Disord. 2019;34(2):210. doi:10.1002/mds.2779530345602
   PubMed Web of Science ®Google Scholar
• Szász JA, Constantin V, Orbán-Kis K, et al. Dopamine agonists in advanced Parkinson’s disease: data from a large cohort of Romanian patients. J Parkinsons Dis. 2019;9(1):128. doi:10.3233/JPD-199900
   Google Scholar
• Worlich Pedersen S, Clausen J, Gregerslund MM. Practical guidance on how to handle levodopa/carbidopa intestinal gel therapy of advanced PD in a movement disorder clinic. Open Neurol J. 2012;6(1):37–50. doi:10.2174/1874205x0120601003722848335
   PubMedGoogle Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–458. doi:10.1002/mds.109011391738
   PubMed Web of Science ®Google Scholar
• Fabbri M, Ferreira JJ, Lees A, et al. Opicapone for the treatment of Parkinson’s disease: a review of a new licensed medicine. Mov Disord. 2018;33(10):1528–1539. doi:10.1002/mds.2747530264443
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29(2):229–237. doi:10.1002/mds.2575124323641
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29(10):1273–1280. doi:10.1002/mds.2596125044402
   PubMed Web of Science ®Google Scholar
• Patel AB, Jimenez-Shahed J. Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date. Neuropsychiatr Dis Treat. 2018;14:2955–2964. doi:10.2147/NDT.S14763330464480
   PubMed Web of Science ®Google Scholar
• Nyholm D, Odin P, Johansson A, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients. AAPS J. 2013;15(2):316–323. doi:10.1208/s12248-012-9439-123229334
   PubMed Web of Science ®Google Scholar
• Othman AA, Dutta S. Population pharmacokinetics of levodopa in subjects with advanced Parkinson’s disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol. 2014;78(1):94–105. doi:10.1111/bcp.1232424433449
   PubMed Web of Science ®Google Scholar
• Müller T, Laar TV, Cornblath DR, et al. Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery. Park Relat Disord. 2013;19(5):501–507. doi:10.1016/j.parkreldis.2013.02.006
   PubMed Web of Science ®Google Scholar
• Liu XD, Bao Y, Liu GJ. Comparison between levodopa-carbidopa intestinal gel infusion and subthalamic nucleus deep-brain stimulation for advanced Parkinson’s disease: a systematic review and meta-analysis. Front Neurol. 2019;10(AUG):1–10. doi:10.3389/fneur.2019.0093430761061
   PubMed Web of Science ®Google Scholar
• Hermanowicz N, Jones SA, Hauser RA. Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey. Neuropsychiatr Dis Treat. 2019;15:2205–2212. doi:10.2147/ndt.s21391731496703
   PubMed Web of Science ®Google Scholar
• Szatmari S, Illigens BMW, Siepmann T, Pinter A, Takats A, Bereczki D. Neuropsychiatric symptoms in untreated Parkinson’s disease. Neuropsychiatr Dis Treat. 2017;13:815–826. doi:10.2147/NDT.S13099728352181
   PubMed Web of Science ®Google Scholar
• Romosan A-M, Romosan R-S, Bredicean AC, Simu MA, Bredicean AC, Simu MA. Affective theory of mind in Parkinson’s disease: the effect of cognitive performance. Neuropsychiatr Dis Treat. 2019;15:2521–2535. doi:10.2147/NDT.S21928831564879
   PubMed Web of Science ®Google Scholar
• Fasano A, Parra JC, Gurevich T, et al. Utilization of monotherapy and combination therapies in advanced Parkinson’s disease patients during levodopa-carbidopa intestinal gel treatment from the cosmos study. J Neurol Sci. 2019;405:212–213. doi:10.1016/j.jns.2019.10.1195
   Web of Science ®Google Scholar
• Regidor I, Santos-Garciá D, Catalán MJ, et al. Impact of disease duration in effectiveness of treatment with levodopa-carbidopa intestinal gel and factors leading to discontinuation. J Parkinsons Dis. 2019;9(1):173–182. doi:10.3233/JPD-18132430562907
   PubMedGoogle Scholar
• Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the definition of advanced Parkinson’s disease: a neurologists-based delphi study (CEPA Study). Parkinsons Dis. 2017;2017:1–8. doi:10.1155/2017/4047392
   Web of Science ®Google Scholar
• Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063–2073. doi:10.1080/03007995.2018.150216530016901
   PubMed Web of Science ®Google Scholar
• Fasano A, Fung VSC, Lopiano L, et al. Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19(1):1–11. doi:10.1186/s12883-019-1276-830606131
   PubMed Web of Science ®Google Scholar
• Lang AE, Rodriguez RL, Boyd JT, et al. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016;31(4):538–546. doi:10.1002/mds.2648526695437
   PubMed Web of Science ®Google Scholar
• Buongiorno M, Antonelli F, Cámara A, et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Park Relat Disord. 2015;21(8):871–876. doi:10.1016/j.parkreldis.2015.05.014
   PubMed Web of Science ®Google Scholar
• Calandrella D, Romito LM, Elia AE, et al. Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology. 2015;84(16):1669–1672. doi:10.1212/WNL.000000000000150025809301
   PubMed Web of Science ®Google Scholar
• Artusi CA, Balestrino R, Imbalzano G, et al. Beyond 10 years of levodopa intestinal infusion experience: analysis of mortality and its predictors. Park Relat Disord. 2019;(October):0–1. doi:10.1016/j.parkreldis.2019.10.004
   Web of Science ®Google Scholar
• Slevin JT, Fernandez HH, Zadikoff C, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinsons Dis. 2015;5(1):165–174. doi:10.3233/JPD-14045625588353
   PubMedGoogle Scholar
• Rajabally YA, Martey J. Neuropathy in Parkinson disease Prevalence and determinants. Neurology. 2011;77(22):1947–1950. doi:10.1212/WNL.0b013e31823a0ee422049200
   PubMed Web of Science ®Google Scholar
• Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L. Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract. 2019;6(2):96–103. doi:10.1002/mdc3.1268830838307
   PubMed Web of Science ®Google Scholar
• Mancini F, Comi C, Oggioni GD, et al. Prevalence and features of peripheral neuropathy in Parkinson’s disease patients under different therapeutic regimens. Park Relat Disord. 2014;20(1):27–31. doi:10.1016/j.parkreldis.2013.09.007
   PubMed Web of Science ®Google Scholar
• Willows T, Dizdar N, Nyholm D, et al. Initiation of levodopa-carbidopa intestinal gel infusion using telemedicine (video communication system) facilitates efficient and well-accepted home titration in patients with advanced Parkinson’s disease. J Parkinsons Dis. 2017;7(4):719–728. doi:10.3233/JPD-16104828984615
   PubMedGoogle Scholar
• Amjad F, Bhatti D, Davis TL, et al. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United States. Adv Ther. 2019;36(9):2233–2246. doi:10.1007/s12325-019-01014-431278691
   PubMed Web of Science ®Google Scholar
• Vijiaratnam N, Hewer S, Varley S, et al. Levodopa-carbidopa intestinal gel: is the naso-jejunal phase a redundant convention? Intern Med J. 2018;48(4):469–471. doi:10.1111/imj.1375429623988
   PubMed Web of Science ®Google Scholar
• Szasz JA, Szatmari S, Constantin V, et al. The importance of evaluation of gastrointestinal features in advanced Parkinson’s disease. Orv Hetil. 2020:161. doi:10.1556/650.2020.31782.
   Web of Science ®Google Scholar
• Szász JA, Orbán-Kis K, Constantin VA, et al. Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients. Neuropsychiatr Dis Treat. 2019;15:831–838. doi:10.2147/NDT.S19763031040682
   PubMed Web of Science ®Google Scholar
• Szász J, Constantin V, Fazakas P, et al. The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson’s disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital. Orv Hetil. 2017;158(51):2023–2028. doi:10.1556/650.2017.3091429250969
   PubMed Web of Science ®Google Scholar
• Szász JA, Constantin V, Mihály I, et al. Dopamine agonists in Parkinson’s disease therapy - 15 years of experience of the neurological clinics from Tirgu Mures. A cross-sectional study. Ideggyogy Sz. 2019;72(5–6):187–193. doi:10.18071/isz.72.018731241263
   PubMedGoogle Scholar